
zzso a potent inhibitor of the pancreatic and zzso zzso is the first member of a new therapeutic class approved for the treatment of zzso Its administration with zzso foods results in a partial zzso of zzso zzso in the zzso zzso and subsequent reduction of the free fatty acids and zzso zzso At the usual dosage of 120 zzso zzso about zzso of zzso fat are zzso non zzso in zzso When administered with a mildly zzso diet, zzso contributes to loss of weight by a additional caloric deficit and promotes further compliance of the obese patient to the dietary zzso Several zzso zzso studies have shown a statistically significant loss of weight of about zzso when zzso was prescribed with a well zzso mildly zzso diet to obese patients during one zzso Moreover, small but significant beneficial changes in the serum zzso levels occurred in these zzso Because the zzso zzso is not zzso its side effects are mostly due to the gastrointestinal effects and consist in zzso after fatty zzso However, the treatment is generally well zzso Since the recent withdrawal from the worldwide market of the zzso agents, zzso and zzso zzso is at this time the only drug approved by the European Community for the treatment of zzso However, its long-term value are not currently zzso 

